Borussertib is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as an inhibitor of Aurora kinase, a specific protein kinase enzyme that plays a key role in regulating cell division and is often overactive in cancer cells, thereby helping to halt the growth and spread of tumors. This compound is particularly significant in research focused on identifying new treatments for cancers that are resistant to conventional therapies, with preliminary studies indicating potential efficacy against types such as breast, lung, and colorectal cancer. Its application in clinical trials aims to assess its efficacy and safety in patients, potentially leading to its use as part of combination therapies or as a standalone treatment for various types of cancer.